Omeros reports Phase II OS data for OMS721 in thrombotic microangiopathy
Omeros Corp. (NASDAQ:OMER) reported data from 18 patients with hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (HCT-TMA) in a Phase II trial and one HCT-TMA patient treated under a compassionate use program showing that once-weekly OMS721 for four or eight weeks significantly increased median overall survival (OS) vs. a matched historical control (347 vs. 21 days, p<0.0001). OMS721 was well tolerated with diarrhea and neutropenia reported as the most common adverse events.
The open-label, international trial is evaluating safety, clinical activity as measured by platelet count, pharmacokinetics and immunogenicity...
BCIQ Company Profiles
BCIQ Target Profiles